服阿基里斯的脚跟:一种化学和结构设计,以解决siRNA治疗中的非目标效应
Rohith Pavan Parvathaneni1, Nithiyanandan Krishnan2, Nikolai Hempel3
1Translational Chemical Biology, Science for Life Laboratory, Department of Chemistry, Ångström Laboratory, Uppsala University, 751 21 Uppsala, Sweden.
JACS Au
|February 27, 2026
概括
这项研究引入了对小干扰RNA (siRNA) 的新化学修饰,以减少意外相互作用. 这一策略增强了RNA干扰 (RNAi) 的特异性,同时保持了它的有效性.
科学领域:
- 分子生物学分子生物学
- 生物化学 生物化学
- 化学生物学 化学生物学
背景情况:
- RNA干扰 (RNAi) 是一种强大的基因沉默技术.
- 非目标效应是RNAi应用的重要限制.
- 尽量减少意外相互作用对于提高RNAi特异性和安全性至关重要.
研究的目的:
- 开发一种新的策略,以减轻RNA干扰 (RNAi) 的非目标效应.
- 将种子区域的化学修饰与感觉链 (SS) 上延长的3'-悬浮相结合.
- 为了减少SS介导和miRNA类非目标相互作用.
主要方法:
- 为siRNA种子区域开发了一种新的2'-二醇化学修饰.
- 为2'-二醇装置合成的通用2'-二酸盐胺.
- 设计结构不对称的siRNA (US-siRNA),在SS.上具有五个核酸3'-超悬.
- 评估了修改对化温度 (Tm) 和RISC负载的影响.
主要成果:
- 种子区域的2'-二醇修饰强加了热力学不对称性,Tm降低了-1至-4.0°C.
- 具有种子区域修改的US-siRNA设计显著增加了反意义链 (AS) RISC负载.
- 综合战略有效地将目标外影响降到最低.
结论:
- 一种简单的模块化策略,结合了2'-二醇种子区域修饰和US-siRNA设计,可以减少目标外影响.
- 这种方法保持了目标RNA干扰 (RNAi) 活性.
- 开发的修改为增强RNAi技术特异性提供了一个有希望的解决方案.
相关概念视频
Structure-Activity Relationships and Drug Design
1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
siRNA - Small Interfering RNAs
18.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.8K
Experimental RNAi
8.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.1K
RNA Interference
28.3K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.3K
Modified-Release Drug Delivery Systems: Site-Targeted
51
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
51
Site-Targeted Drug Delivery Systems: Polymeric Carriers
59
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
59


